The genome-wide association study of the principal components of the metabolic syndrome enriched with albumin/creatinine ratio regarding the OPTI-THERA research project

This project used the CARTaGENE cohort to replicate genetic signals related to metabolic syndrome and the albumin‑to‑creatinine ratio (ACR), an important kidney marker linked to cardiovascular risk. In the first phase, a study conducted in the Czech Republic had identified genetic variants that may influence both metabolic profiles and albuminuria.
The project evaluated these findings in CARTaGENE by analyzing about 754 French‑Canadian adults, selected to be representative of the population by age, sex, and cardiovascular risk. CARTaGENE’s extensive genetic and biological data enabled a robust assessment of reproducibility.
Complementary research conducted in CARTaGENE has also shown that genes involved in uric‑acid handling (including SLC2A9) and kidney markers such as uromodulin can influence albuminuria, reinforcing the value of studying genetics, kidney function, and metabolic factors together.
This project contributes to a better understanding of the biological pathways linking metabolism, kidney health, and cardiovascular risk.

• Chronic diseases
• Genetics and genomics

• Biochemical and hematological data
• Physical and cognitive measures
• Questionnaire data